Quick search:
Content Search
Result Content Research
Result Content Research
1 Praxis Precision Medicines (PRAX) falls 0.31% on Moderate Volume July 26
2 How Many Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Do Institutions Own?
3 Praxis Precision Medicines to Present at Upcoming Investor Conferences
4 What Kind Of Shareholders Own Praxis Precision Medicines, Inc. (NASDAQ:PRAX)?
5 The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
6 May 11, 2021 Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
7 Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
8 Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
9 Praxis Precision Medicines Inc. (PRAX) Q4 2020 Earnings Call Transcript
10 May 13, 2021 Praxis Precision Medicines Prices Public Offering of Common Stock
11 Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
12 Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
13 April 14, 2021 Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment
14 Praxis Precision Medicines Expands Leadership Team to Advance its Pipeline for CNS Disorders
15 December 01, 2020 Praxis Precision Medicines Announces CFO Transition
16 Fresh Off a $110 Million Series C, Praxis Precision Medicines Eyes $190 Million IPO
17 Praxis Precision Medicines Announces $110 Million Financing
18 Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation
19 Praxis Precision Medicines Receives Rare Pediatric Disease
20 Praxis Precision Medicines upsizes IPO by 35%, now looks to raise up to $180 million
21 Praxis Precision Medicines (PRAX) Plans Public Offering of Common Stock
22 Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters
23 Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders
24 November 17, 2020 Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment
25 The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
26 Praxis Precision Medicines Readies $126 Million IPO
27 PRAX Stock Forecast, Price & News (Praxis Precision Medicines)
28 Praxis Precision Pops 62% as Biotech IPO Party Continues
29 Praxis Precision Medicines Inc (PRAX) gains 2.8660% for June 25
30 Praxis Precision Medicines launches with $100M and bold sights on long-evasive neurological disorders
31 Praxis Precision Medicines Promotes Business Leader Stuart Chaffee to Chief Financial Officer
32 Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
33 Why Is Coupa Software (COUP) Up 27.6% Since Last Earnings Report?
34 Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
35 A few months after emerging from stealth, Praxis is handed a clinical hold for lead depression drug
36 2021 Major Depressive Disorder Pipeline Insight Report: Insights for Approx 50+ Companies and 50+ Pipeline Drugs
37 How to Optimize Success in Clinical Trials of Antidepressants
38 Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors
39 Hummingbird Bioscience buzzes with $125M series C led by Novo Holdings
40 Using AI/ML to reduce the costs and risks of CNS diseases research
41 Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease :: Scrip
42 Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy :: Scrip
43 Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer
44 The Petri Dish: NeuroBo acquires year-old startup; two biotechs launch
45 Movers & Shakers, May 28 | BioSpace
46 Our First Look At Relmada Therapeutics
47 Taking A Life Science Company Public During A Pandemic
48 51 Biggest Movers From Yesterday – Benzinga
49 Endowment Sells Off Stocks in Major Technology Companies, Invests in Microsoft and Biopharmaceutical Companies in Fourth Quarter | News
50 The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
51 50 Biggest Movers From Friday
52 The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
53 The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit
54 The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
55 30 Stocks Moving In Wednesday's Mid-Day Session
56 Appointments and advancements for May 25, 2021 | 2021-05-25
57 The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
58 Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
59 Foghorn Therapeutics Rises 13% in Market Debut
60 The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
61 PTC Therapeutics Announces Management Change
62 The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
63 Epilepsy Pipeline Review 2020: Therapeutic Analysis Report Featuring 140+ Companies & Drug Profiles
64 Codiak BioSciences Stock Falls in Market Debut
65 Q-State Biosciences Announces the Appointment of Biopharma Veteran Paul Medeiros as President and Chief Executive Officer
66 Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021
67 Boeing, Galapagos, Intuitive Surgical: What to Watch When the Stock Market Opens Today
68 The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
69 Hearing-Aid Maker Eargo Soars 87% in Its First Trading Day
70 The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
71 06.25.21 -- Why A CEO Went From Academia To Biopharma
72 Seeking Alpha Catalyst Watch
73 2020 Epilepsy Pipeline Conference
74 Axsome Therapeutics (AXSM) Receives a Buy from William Blair
75 Clean tech is getting a fresh slate in 2020
76 FDA panel considering Alkermes' combo tablet in schizophrenia, bipolar I
77 Genentech alum Jane Grogan goes startup hopping from ArsenalBio to Graphite Bio; Scott Holmes to handle CFO duties at Catamaran Bio, teaming up again with ex-Disarm CEO
78 Recursion CSO heads west for mini-brain upstart; Novartis vet steps up to the plate as CFO for Andrew Hirsch at C4 Therapeutics
79 Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
80 Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures
81 Automated and Closed Cell Therapy Processing Systems Markets, 2030
82 WorkBoard's new chat-first experience makes OKR adoption easier than ever
83 60 Stock Price Gainers And Losers (March 19, 2021)
84 A pair of Bayer execs land promotions in the US; Energized by lenzilumab data, Humanigen taps AstraZeneca alum as CMO
85 Stocks That Hit 52-Week Highs On Friday
86 The 14 Largest US Tech Startup Funding Rounds of July 2020
87 Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts, Upcoming Webinar Hosted by Xtalks
88 Business Advisory Board
89 Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation
90 Bio Roundup: Cerevel's Shell, Thrive's Rise, Drug Price Drama & More
91 Relay Therapeutics acquires startup ZebiAI for $85M
92 Worldwide Depression Pipeline Guide, H1 2020: Therapeutics,
93 Bio Roundup: MESO's Miss, Pfizer's Cancer Bet, Vaccine Promise & More
94 With GlaxoSmithKline in the rearview mirror, Abbas Hussain is ready to lead a biotech of his own; Doug Treco scores first CEO job since Ra Pharma buyout
95 Gene Therapy Shows Initial Promise for Parkinson's Disease
96 Vedanta Biosciences taps Big Pharma vet Jeffrey Silber as CMO; Robert Doebele leaves behind teaching post at Colorado to focus on CSO job at Rain Therapeutics
97 IPA Stock Forecast, Price & News (ImmunoPrecise Antibodies)
98 Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins
99 TNH's 50 Wealthiest Greeks in America List 2021: Numbers 30-21 | community , general news
100 Coupa Software Reports First Quarter Fiscal 2022 Financial Results